VOYA Investment Management
ARQT icon

VOYA Investment Management’s Arcutis Biotherapeutics ARQT Stock Holding History

VOYA Investment Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$572K Buy
21,801
+2,911
+15% +$67.8K ﹤0.01% 1751
2026
Q1 		$445K Sell
18,890
-20,994
-53% -$536K ﹤0.01% 1771
2025
Q4 		$1.16M Buy
39,884
+20,620
+107% +$528K ﹤0.01% 1432
2025
Q3 		$363K Sell
19,264
-10,105
-34% -$159K ﹤0.01% 1908
2025
Q2 		$412K Buy
29,369
+313
+1% +$4.39K ﹤0.01% 1981
2025
Q1 		$454K Sell
29,056
-3,080
-10% -$43.4K ﹤0.01% 1908
2024
Q4 		$448K Sell
32,136
-2,472
-7% -$27.1K ﹤0.01% 1992
2024
Q3 		$322K Sell
34,608
-806
-2% -$7.95K ﹤0.01% 2231
2024
Q2 		$329K Buy
35,414
+9,258
+35% +$83.7K ﹤0.01% 2212
2024
Q1 		$259K Sell
26,156
-67,056
-72% -$500K ﹤0.01% 2329
2023
Q4 		$301K Buy
93,212
+54,930
+143% +$149K ﹤0.01% 2344
2023
Q3 		$203K Buy
38,282
+707
+2% +$6.01K ﹤0.01% 2534
2023
Q2 		$358K Buy
37,575
+4,944
+15% +$54.9K ﹤0.01% 2260
2023
Q1 		$359K Sell
32,631
-2,740
-8% -$39.6K ﹤0.01% 2229
2022
Q4 		$523K Hold
35,371
– – ﹤0.01% 2015
2022
Q3 		$676K Buy
35,371
+22,246
+169% +$504K ﹤0.01% 1840
2022
Q2 		$280K Buy
13,125
+2,385
+22% +$48.9K ﹤0.01% 2214
2022
Q1 		$207K Hold
10,740
– – ﹤0.01% 2348
2021
Q4 		$223K Sell
10,740
-39
-0.4% -$776 ﹤0.01% 2446
2021
Q3 		$258K Hold
10,779
– – ﹤0.01% 2422
2021
Q2 		$294K Buy
10,779
+1,343
+14% +$37.8K ﹤0.01% 2385
2021
Q1 		$273K Buy
9,436
+1,003
+12% +$31.3K ﹤0.01% 2363
2020
Q4 		$237K Buy
+8,433
New +$207K ﹤0.01% 2334

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

VOYA Investment Management's ARQT Position: Q2 2026 in Review

VOYA Investment Management increased its Arcutis Biotherapeutics (ARQT) stake by 15% in Q2 2026, buying an estimated $67.8K and bringing the position to 21,801 shares worth $572K. The position accounts for ﹤0.01% of the portfolio, ranked #1751.

VOYA Investment Management first reported a position in ARQT in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.16M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • VOYA Investment Management held 21,801 shares of Arcutis Biotherapeutics worth $572K as of Q2 2026.
  • VOYA Investment Management bought 2,911 Arcutis Biotherapeutics shares in Q2 2026, an estimated $67.8K.
  • Arcutis Biotherapeutics made up ﹤0.01% of VOYA Investment Management's portfolio in Q2 2026, its #1751 holding.
  • VOYA Investment Management first reported a position in Arcutis Biotherapeutics in Q4 2020 and has held it in 23 quarters since.
  • VOYA Investment Management's Arcutis Biotherapeutics position peaked at $1.16M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.